US Pharma MarketingThe post Tyra announces initial data from Phase II SURF302 trial of dabogratinib appeared first on Clinical Trials Arena.
Tyra announces initial data from Phase II SURF302 trial of dabogratinib
Tyra Biosciences has reported initial data from its Phase II SURF302 clinical trial of the oral drug dabogratinib in FGFR3-altered low-grade intermediate-risk non-muscle invasive bladder cancer (LG IR NMIBC) patients. In the trial, dabogratinib’s safety profile was evaluated in 60mg and 50mg once-daily cohorts, each with 22 participants. For efficacy, 26 participants were evaluable across both dose groups. Credit: Sai Thaw Kyar / Shutterstock.com. Tyra Biosciences has reported initial data from its Phase II SURF302 clinical trial of the oral drug dabogratinib in FGFR3-altered low-grade intermediate-risk non-muscle invasive bladder cancer (LG IR NMIBC) patients. The data provided the first clinical…
Tyra Biosciences has reported initial data from its Phase II SURF302 clinical trial of the oral drug dabogratinib in FGFR3-altered low-grade intermediate-risk non-muscle invasive bladder cancer (LG IR NMIBC) patients.
Source: Clinical Trials Arena